Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01184
|
|||||
| Drug Name |
Nitric oxide
|
|||||
| Synonyms |
HNO; ()NO; 10102-43-9; AC1L3QHF; Bioxyde d'azote; Bioxyde d'azote [French]; CHEBI:16480; CHEMBL1200689; CTK0H7679; DTXSID1020938; EDRF; Endogenous Nitrate Vasodilator; Endothelium-Derived Nitric Oxide; Endothelium-derived relaxing factor (EDRF); INOmax; INOmax (TN); Mononitrogen monoxide; Monoxide, Mononitrogen; Monoxide, Nitrogen; Monoxido de nitrogeno; Monoxyde d'azote; NITRIC-OXIDE; NO(); Nitrate Vasodilator, Endogenous; Nitric Oxide, Endothelium Derived; Nitric Oxide, Endothelium-Derived; Nitric oxide; Nitric oxide (JAN); Nitric oxide 10% by volume or more; Nitric oxide trimer; Nitric oxide, 985%; Nitric oxide, compressed [UN1660] [Poison gas]; Nitrogen monoxide; Nitrogen oxide (NO); Nitrogen(II) oxide; Nitrosoradical; Nitrosyl; Nitrosyl hydride; Nitrosyl hydride ((NO)H); Nitrosyl radical; Nitroxide radical; Nitroxyl; OHM 11771; Oxide, Nitric; Oxido de nitrogeno(II); Oxido nitrico; Oxidonitrogen; Oxoazanyl; Oxyde azotique; Oxyde nitrique [French]; Stickmonoxyd; Stickmonoxyd [German]; Stickstoff(II)-oxid; Stickstoffmonoxid; Vasodilator, Endogenous Nitrate; [NO]; endothelium-derived relaxing factor; monoxido de nitrogeno; monoxyde d'azote; nitric oxide; nitrogen monoxide; nitrogen protoxide; nitrosyl; oxido de nitrogeno(II); oxido nitrico; oxidonitrogen; oxoazanyl; oxyde azotique
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Platelet dysfunction [ICD11:3B62] | Phase 2/3 | [1] | |||
| Therapeutic Class |
Bronchodilator Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
NO
|
|||||
| Canonical SMILES |
[N]=O
|
|||||
| InChI |
InChI=1S/NO/c1-2
|
|||||
| InChIKey |
MWUXSHHQAYIFBG-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 10102-43-9
|
|||||
| Pharmaceutical Properties | Molecular Weight | 30.006 | Topological Polar Surface Area | 18.1 | ||
| Heavy Atom Count | 2 | Rotatable Bond Count | 0 | |||
| Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 1 | |||
| XLogP |
0.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10248789
,10322712
,10502255
,11532572
,11532575
,11533089
,11538857
,11538865
,14715948
,3009
,3815
,584758
,584760
,585304
,612541
,6435917
,6436059
,6436465
,7847142
,8009073
,8024763
,8025088
,819430
,819437
,823106
,825225
,827786
,827830
,829083
,829196
,830346
,831905
,832739
,832741
,832746
,832749
,835684
,835924
,835946
,835951
,837432
,837589
,838043
,838516
,838735
,838738
,838741
,841103
,854516
,854518
|
|||||
| ChEBI ID |
ChEBI:16480
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | ASCT2 | Transporter Info | Alanine/serine/cysteine/threonine transporter 2 | Substrate | [2] | |
| References | ||||||
| 1 | ClinicalTrials.gov (NCT03455218) Nitric Oxide Administration During Pediatric Cardiopulmonary Bypass Surgery to Prevent Platelet Activation | |||||
| 2 | Functional regulation of Na+-dependent neutral amino acid transporter ASCT2 by S-nitrosothiols and nitric oxide in Caco-2 cells. FEBS Lett. 2005 Apr 25;579(11):2499-506. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.